The MD Anderson Cancer Center CCOP Research Base (RB) is a venue for transdisciplinary cancer control research within MDACC, and connecting this research to community oncologists and other academic centers, in order to improve patient care. Hypothesis: our cancer center RB, using its full breadth and scope of clinicians, basic and population science researchers, community partners, and robust expertise in all aspects of clinical investigation, while leveraging the resources available at MDACC, can create and disseminate critical new knowledge in cancer control through the process of team science and clinical research innovation.
Specific aims :
Aim 1. To conduct interventional clinical trials and other prospective studies in the realm of cancer control to enhance the health and well-being of patients affected by cancer or at risk for cancer recurrence. (1a) To develop and conduct clinical trials and other prospective studies in integrative health in order to optimize health, quality of life, and clinical outcomes of patients and families across the cancer continuum;(1b) To develop and conduct interventional trials and prospective studies directed at understanding and reducing the burden of cancer treatment toxicity;(1c) To incorporate novel approaches to the design, conduct, and analysis of clinical trials.
Aim 2. To promote cancer control science among our community oncology sites, academic cancer center faculty and fellows, and the lay public. (2a) To enhance interactions between preclinical and clinical investigators to better inform the design of clinical trials and enhance the collection and interpretation of pilot data and correlative science;(2b) To develop cancer control studies relevant to all stakeholders and involving the collection of patient-reported outcome data and data related to observed patient behaviors;(2c) To use multiple modes of communication to disseminate the healthy goals and step-by-step processes involved in cancer control research;(2d) To use mentorship and institutional leadership to promote the inclusion of young investigators and women physicians and scientists in the CCOP research base;(2e) To develop and share best practices for the inclusion of underrepresented populations in our clinical research studies and on our research teams.

Public Health Relevance

The MD Anderson Cancer Center CCOP Research Base delivers innovative studies directly to patients in the community setting, in order to improve patient care and facilitate the discovery and dissemination of new information that impacts the field of cancer medicine.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-B (J1))
Program Officer
Brell, Joanna M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
Internal Medicine/Medicine
Other Domestic Higher Education
United States
Zip Code
Siefker-Radtke, Arlene O; Campbell, Matthew T; Munsell, Mark F et al. (2016) Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study. Urology 89:83-9
Penas-Prado, Marta; Hess, Kenneth R; Fisch, Michael J et al. (2015) Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol 17:266-73
Oki, Yasuhiro; Ewer, Michael S; Lenihan, Daniel J et al. (2015) Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial. Clin Lymphoma Myeloma Leuk 15:152-8
Mitri, Zahi; Karakas, Cansu; Wei, Caimiao et al. (2015) A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs 33:890-4
Lewis, Mark A; Zhao, Fengmin; Jones, Desiree et al. (2015) Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective Multicenter Study. J Pain Symptom Manage 49:1016-24
Minasian, Lori M; Tangen, Catherine M; Wickerham, D Lawrence (2015) Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program. Semin Oncol 42:748-63
Bilen, Mehmet Asim; Johnson, Marcella M; Mathew, Paul et al. (2015) Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121:69-76
Bayraktar, Soley; Gutierrez Barrera, Angelica M; Liu, Diane et al. (2013) USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer. Cancer J 19:10-7
Parker, Patricia A; Urbauer, Diana; Fisch, Michael J et al. (2013) A multisite, community oncology-based randomized trial of a brief educational intervention to increase communication regarding complementary and alternative medicine. Cancer 119:3514-22
Bayraktar, Soley; Avery, Tiffany; Altundag, Kadri et al. (2013) Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients. Breast J 19:431-4

Showing the most recent 10 out of 38 publications